Insider at ProMIS Neurosciences (PMN) buys 2,280 common shares

Rhea-AI Filing Summary

Johanne Kaplan, Chief Development Officer of ProMIS Neurosciences Inc., purchased 2,280 Common Shares on August 5, 2026 in a purchase classified as an open market or private transaction at $13.30 per share. After this transaction, Kaplan directly owns 6,221 Common Shares of the company.

Insider Trade Summary

Net Buyer: 2,280 shares

Net Buy 1 txn

Insider Kaplan Johanne

Role Chief Development Officer

Bought 2,280 shs ($30K)

Type	Security	Shares	Price	Value
Purchase	Common Shares	2,280	$13.30	$30K

Holdings After Transaction: Common Shares — 6,221 shares (Direct)

Key Figures

Shares purchased: 2,280 Common Shares Purchase price per share: $13.30 Shares owned after transaction: 6,221 Common Shares +1 more

4 metrics

Shares purchased 2,280 Common Shares Non-derivative purchase by Chief Development Officer on August 5, 2026

Purchase price per share $13.30 Price per Common Share in the August 5, 2026 transaction

Shares owned after transaction 6,221 Common Shares Direct holdings of Johanne Kaplan following the reported purchase

Net shares bought in report 2,280 Net buy shares across all reported transactions

Key Terms

Common Shares, non-derivative, open market or private transaction

3 terms

Common Shares financial

"security_title": "Common Shares", "transaction_date""

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

non-derivative financial

""transaction_type": "non-derivative", "transaction_shares""

open market or private transaction financial

""transaction_code_description": "Purchase in open market or private transaction""

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/07/2026 - 04:00 PM Accepted by SEC EDGAR 08/07/2026 - 04:00 PM Learn about SEC filing dates

FAQ

What insider share purchase did ProMIS Neurosciences (PMN) report?

ProMIS Neurosciences reported that Chief Development Officer Johanne Kaplan bought 2,280 Common Shares on August 5, 2026 at $13.30 per share, increasing her direct holdings to 6,221 shares.

Who is Johanne Kaplan at ProMIS Neurosciences (PMN)?

Johanne Kaplan is the Chief Development Officer of ProMIS Neurosciences Inc. She recently purchased 2,280 Common Shares of the company, bringing her direct ownership to 6,221 shares following the August 5, 2026 transaction.

How many ProMIS Neurosciences (PMN) shares does Johanne Kaplan own after the transaction?

Following the reported purchase, Johanne Kaplan directly owns 6,221 Common Shares of ProMIS Neurosciences. This reflects the addition of 2,280 shares acquired on August 5, 2026 in a non-derivative, open market or private transaction.

At what price did Johanne Kaplan buy ProMIS Neurosciences (PMN) shares?

Johanne Kaplan purchased ProMIS Neurosciences Common Shares at $13.30 per share. On August 5, 2026, she acquired 2,280 shares in a non-derivative transaction classified as a purchase in an open market or private transaction.

Was Johanne Kaplan’s ProMIS Neurosciences (PMN) trade under a Rule 10b5-1 plan?

The report indicates the Rule 10b5-1 checkbox was not selected for this transaction. This means the disclosed purchase of 2,280 Common Shares on August 5, 2026 was not affirmed as made under a Rule 10b5-1 trading plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaplan Johanne

(Last) (First) (Middle)

C/O PROMIS NEUROSCIENCES INC.

SUITE 200, 1920 YONGE STREET

(Street)

TORONTO M4S 3E2

(City) (State) (Zip)

ONTARIO, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
ProMIS Neurosciences Inc. [ PMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	08/05/2026		P		2,280	A	$13.3	6,221	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Max A. Milbury, Attorney in Fact for Johanne Kaplan	08/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)